Pages that link to "Item:Q4349992"
From MaRDI portal
The following pages link to A Random Walk Rule for Phase I Clinical Trials (Q4349992):
Displaying 26 items.
- A conversation with Nancy Flournoy (Q254418) (← links)
- Sequential design for binary dose-response experiments (Q301360) (← links)
- Information in a two-stage adaptive optimal design (Q389442) (← links)
- On the consistency of the continual reassessment method with multiple toxicity constraints (Q499432) (← links)
- Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
- Randomized group up and down experiments (Q1039833) (← links)
- Operating characteristics of the standard phase I clinical trial design. (Q1285808) (← links)
- Properties of frequency distributions induced by general ''up-and-down'' methods for estimating quantiles (Q1298913) (← links)
- On optimal designs for clinical trials: an updated review (Q2301225) (← links)
- Individualized dosing for multiple ordered groups of patients (Q2320813) (← links)
- An application of reinforced urn processes to determining maximum tolerated dose (Q2373664) (← links)
- A new look at evaluating MTD designs in cancer research (Q2431683) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Up-and-down experiments of first and second order (Q2485984) (← links)
- Group up-and-down designs for dose-finding (Q2492509) (← links)
- Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression (Q3078921) (← links)
- Bayesian Optimal Designs for Phase I Clinical Trials (Q3079157) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- Continual reassessment method with multiple toxicity constraints (Q3303685) (← links)
- Designs for Single- or Multiple-Agent Phase I Trials (Q3445286) (← links)
- Derivation of Exact Distributions Following an Up-and-Down Design (Q3645036) (← links)
- A sequential design for maximizing the probability of a favourable response (Q4222063) (← links)
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477) (← links)
- A new design of the continual reassessment method (Q5082671) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials (Q5438331) (← links)
